A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)
This study has been terminated.
( Based on analysis of results and consideration of available treatments, the overall benefit to risk profile of ocrelizumab was not favorable in RA. )
Study NCT00406419
Information provided by Genentech
First Received on November 30, 2006.
Last Updated on June 25, 2010
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
